Zhu Z, Chai Y., et al. - Because epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy represents an effective therapeutic choice for advanced lung cancer harboring EGFR gene mutations, researchers assessed progression-free survival as well as response rate in 30 stage I non-small-cell lung cancer patients harboring EGFR gene mutations with postoperative intrapulmonary recurrence. In 23 patients partial response was seen, while stable disease was evident in 7 patients. The objective response rate and disease control rate were estimated to be 76.7% and 100%, respectively. A median progression-free survival (PFS) of 24.5 months was achieved. In cases with only intrapulmonary recurrence, a significantly superior median PFS was observed vs cases with both intrapulmonary recurrence and metastasis. In cases treated with icotinib vs those managed with gefitinib, a significantly longer median PFS was noted. Overall, findings indicated the effectiveness of first-line EGFR-TKIs treatment for stage I non-small-cell lung cancer patients harboring EGFR gene mutations with postoperative intrapulmonary recurrence. Based on these data, first-line EGFR-TKIs could serve as a beneficial choice in a practical setting.